TREGCEL™, A REGULATORY T CELL THERAPY PLATFORM
A novel therapeutic approach for organ transplant and autoimmune diseases.
TRACT Therapeutics, Inc. is developing a personalized product, TregCel™, which can be used to treat solid organ transplant patients and patients suffering from an autoimmune disorder.
The product consists of a patient’s own regulatory T cells, which are expanded in a laboratory and given back to the patient as a single dose by infusion with the goal of establishing immune tolerance.
SIGNIFICANT CLINICAL NEED
Solid Organ Transplant
TregCel™ has the potential to prevent transplant rejection while reducing the need for potentially harmful, life-long immunosuppressive drug therapy.
In 2022, over 42,000 Americans underwent organ transplant surgery.
At least 50% of transplanted organs start a rejection process within 10 years.
Transplant patients require life-long use of immunosuppressive drugs to prevent transplant rejections.
TregCel™ has the potential to transfer a patient into a state of remission and reduce or eliminate the need for potentially harmful, life-long immunosuppression drug therapy.
There are approximately 24 million Americans suffering from at least one autoimmune disease.
Patients who suffer from an autoimmune disease require life-long use of potentially toxic immunosuppressive drugs to suppress their disease.
EARLY CLINICAL SUCCESS
TregCel™ granted Orphan Drug Designation for the prevention of graft rejection following solid organ transplantation.
A Phase 1 clinical trial in kidney transplant demonstrated no safety concerns, and two-year patient biopsies were normal with no rejection.